FDA draft guidance expands single-trial effectiveness pathway

In June 2026, the FDA released a revised draft guidance, Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products, that clarifies when sponsors may rely on a single adequate and well-controlled clinical investigation, supported by confirmatory evidence, to meet the statutory substantial-evidence standard under FD&C Act §505(d). The document is a draft issued for comment, not binding guidance. The agency has opened a comment period through 22 September 2026 under docket FDA-2019-D-4964, and the guidance would replace the 1998 document on the same standard once it is finalized.

The draft sets out conditions under which one trial plus confirmatory evidence could support a conclusion of effectiveness. It does not change the statute. Legal analysis from McGuireWoods notes that the substantial-evidence standard itself is unchanged, and that the confirmatory evidence FDA describes may include related trial data, mechanistic evidence, natural history data, or real-world data, "where such evidence is scientifically sound and legally permissible." McGuireWoods also reads the change as most consequential for rare disease and pediatric development.

How the single-trial route fits the existing standard

Section 505(d) has historically referred to adequate and well-controlled "investigations" in the plural. The single-trial route is a carve-out that depends on FDA's affirmative, science-based determination rather than an automatic entitlement. The draft lists practical and ethical considerations the agency weighs, including whether it is ethical and practicable to conduct more than one adequate and well-controlled trial.

That framing carries particular weight for rare disease and pediatric programs, where the eligible population is often small and geographically dispersed. Under the US statutory definition, a rare disease affects fewer than 200,000 people, and the draft discusses regulatory flexibility for rare, serious, and unmet-need conditions as available rather than guaranteed. In these programs, running a confirmatory trial and a separate replication trial is frequently neither practicable nor ethical, which is the situation the single-trial route is meant to address.

Why recruitment becomes the evidentiary question

Two requirements do most of the work in the single-trial route.

First, where strong external confirmatory evidence is not already available, the draft states that a single, highly persuasive trial should "enroll a broad and representative population across multiple sites," generalizable to US clinical practice. It recommends eligibility criteria that reflect the intended-use population across age, sex, race, ethnicity, and disease severity, with exclusions only where scientifically justified. That points development teams toward representative enrollment and careful stratification rather than the most convenient cohort.

Second, the confirmatory evidence has to come from somewhere. The draft describes categories that include mechanistic evidence, relevant for single-gene or enzyme-deficiency diseases where a drug corrects the underlying defect; natural history data and registries; and real-world data. Each carries conditions. Natural history evidence should come from a source distinct from any data used as a control in the trial, and the appropriateness of real-world data depends on the reliability and relevance of the source, the study design, and prespecified statistical methods, referencing FDA's July 2024 guidance on real-world data from electronic health records.

Both requirements are patient-finding and data problems before they are statistical ones. Representative enrollment depends on identifying and qualifying patients who reflect the intended-use population, not only those closest to a major site. Confirmatory natural-history and real-world evidence depends on capturing longitudinal data from those patients over time. Enrollment is already the common point of failure: Applied Clinical Trials reports that nearly 80% of trials fail to meet their initial enrollment targets and timelines, a figure drawn from general trial populations that describes initial timelines rather than overall trial outcomes.

Building the evidence starts before the trial does

The practical consequence is that the evidence a single-trial submission rests on is assembled long before analysis begins. An operational layer for patient identification and data continuity becomes part of the evidence strategy rather than downstream logistics.

Sano's platform is organized around that layer. Precision recruitment and referral identify genetically defined patients across multiple countries and sites, which supports the broad, representative cohort the draft describes. At-home saliva DNA testing, run through GxP and CLIA/CAP laboratories and covering whole exome and genome sequencing, single and multi-gene panels, and genotyping, confirms eligibility without requiring patients to travel to a site. Prescreening and digital consent shorten onboarding, and EHR retrieval contributes to the longitudinal record that natural-history and real-world analyses draw on.

Long-term engagement connects these steps across a program. By staying connected to participants before, during, and between studies, sponsors can build the recontactable cohorts and long-term follow-up data that function as confirmatory-evidence infrastructure. The same continuous connection that improves enrollment also produces the independent natural-history record the draft treats as a distinct evidentiary source.

What to watch through September

Because the guidance is a draft, its language may change before it is finalized. The comment period runs through September 22, 2026, and sponsors with rare disease, pediatric, or genetically defined programs have a direct interest in how the final version treats representative enrollment and confirmatory evidence.

The open question for development teams is organizational. If a single trial has to carry a representative population and be paired with independent natural-history or real-world evidence, then patient identification and longitudinal data capture move upstream into trial design and feasibility. Teams that treat them as core evidentiary infrastructure, rather than tasks handed to recruitment vendors after a protocol is fixed, will be better positioned to produce both the representative cohort and the confirmatory record the draft points to.

Sano works with sponsors on this layer of program design. Get in touch to discuss how precision patient identification and long-term data capture fit a specific program.